ActivX Biosciences Publishes Two Key Articles Demonstrating Breadth of Applications for KiNativ(R) Technology in Drug Discovery LA JOLLA, CA--(Marketwired - Oct 20, 2016) -  ActivX Biosciences, Inc., a wholly-owned subsidiary of Kyorin Pharmaceutical Co., Ltd. (Tokyo), announces two reports published in high profile,...

Going KiNativ(TM): ActivX Publishes Landmark Article on Kinase Profiling LA JOLLA, CA--(Marketwire - Jul 6, 2011) - ActivX Biosciences, Inc. announced today the publication of "In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases" in the...

Activx Biosciences Head Receives Distinguished Scientist Award LA JOLLA, CA--(Marketwire - January 4, 2010) - Dr. John W. Kozarich, Chairman & President of Activx Biosciences, Inc. (La Jolla, CA), has received the 2009 Distinguished Scientist Award from the...

Activx Biosciences, Inc. Announces Positive Phase Ib and IIa Clinical Trial Results for KRP-104, a Flexible Dosing DPP-4 Inhibitor for Type 2 Diabetes LA JOLLA, CA--(Marketwire - August 21, 2008) - Activx Biosciences, Inc., a wholly owned subsidiary of Tokyo-based Kyorin Pharmaceutical Co., Ltd., announced today topline results from their Phase Ib...